- Home
- VTYX vs NKTR Comparison
VTYX vs NKTR Comparison
Compare VTYX & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- NKTR
- Stock Information
- Founded
- VTYX 2018
- NKTR 1990
- Country
- VTYX United States
- NKTR United States
- Employees
- VTYX N/A
- NKTR N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- NKTR Health Care
- Exchange
- VTYX Nasdaq
- NKTR Nasdaq
- Market Cap
- VTYX 154.9M
- NKTR 125.5M
- IPO Year
- VTYX 2021
- NKTR 1994
- Fundamental
- Price
- VTYX $2.26
- NKTR $8.51
- Analyst Decision
- VTYX Buy
- NKTR Strong Buy
- Analyst Count
- VTYX 4
- NKTR 6
- Target Price
- VTYX $11.33
- NKTR $73.75
- AVG Volume (30 Days)
- VTYX 2.3M
- NKTR 352.6K
- Earning Date
- VTYX 08-07-2025
- NKTR 08-07-2025
- Dividend Yield
- VTYX N/A
- NKTR N/A
- EPS Growth
- VTYX N/A
- NKTR N/A
- EPS
- VTYX N/A
- NKTR N/A
- Revenue
- VTYX N/A
- NKTR $87,248,000.00
- Revenue This Year
- VTYX N/A
- NKTR N/A
- Revenue Next Year
- VTYX N/A
- NKTR N/A
- P/E Ratio
- VTYX N/A
- NKTR N/A
- Revenue Growth
- VTYX N/A
- NKTR N/A
- 52 Week Low
- VTYX $0.78
- NKTR $6.48
- 52 Week High
- VTYX $3.39
- NKTR $22.79
- Technical
- Relative Strength Index (RSI)
- VTYX 56.94
- NKTR 42.19
- Support Level
- VTYX $2.10
- NKTR $7.99
- Resistance Level
- VTYX $2.42
- NKTR $9.71
- Average True Range (ATR)
- VTYX 0.22
- NKTR 1.37
- MACD
- VTYX -0.02
- NKTR -0.20
- Stochastic Oscillator
- VTYX 53.99
- NKTR 11.66
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.